Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Stemcell United Ltd. ( (AU:BP8) ) just unveiled an update.
Apertus Capital Pty Ltd has filed a notice that it has ceased to be a substantial shareholder in BPH Global Ltd following dilution arising from a share issue. The filing indicates that Apertus now has no voting power in BPH Global, and that there has been no change in its association status, signalling a reduced influence on the company’s shareholder base without any transactional consideration disclosed.
The notice, lodged under section 671B of the Corporations Act 2001, reflects regulatory requirements for transparency around movements in substantial holdings on the Australian market. For BPH Global investors, the change clarifies that Apertus no longer exerts substantial holder influence, while the dilution-driven shift underscores the impact that new share issues can have on existing investors’ percentage interests.
The most recent analyst rating on (AU:BP8) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Stemcell United Ltd. stock, see the AU:BP8 Stock Forecast page.
More about Stemcell United Ltd.
Stemcell United Ltd. is an Australian-listed company, but this filing instead concerns BPH Global Ltd., whose shares are held by Apertus Capital Pty Ltd. The document is a regulatory disclosure under the Corporations Act 2001 relating to substantial shareholdings in BPH Global, rather than describing Stemcell United’s operations or markets.
Current Market Cap: A$4.71M
Find detailed analytics on BP8 stock on TipRanks’ Stock Analysis page.